Special episode: Meet the Analyst & From the helm with Mesoblast & John Hester скачать в хорошем качестве

Special episode: Meet the Analyst & From the helm with Mesoblast & John Hester

In this special episode of From the Helm and Meet the Analyst, Bell Financial Group’s Grady Wulff is joined by Mesoblast (ASX:MSB) Managing Director, Silviu Itescu and Bell Potter Healthcare Analyst, John Hester to discuss the company’s latest milestones - including the FDA approval of Ryoncil, its first-ever US sales, and the promising outlook for its second drug candidate, Revascor for heart failure. In this interview Grady covers: • What graft vs host disease is, and how Ryoncil works to treat it • Why the FDA placed such importance on potency and consistency during approval • A breakdown of Ryoncil’s first US sales figures and revenue expectations • Updates on the DREAM HF trial and the regulatory pathway for Revascor How the commercialisation strategy differs between the two indications • Lessons learned from the Ryoncil approval process and advice Silviu would give his past self. Find Bell Direct here: Twitter:   / belldirect   Facebook:   / belldirectau.  . LinkedIn:   / bell.  . Instagram:   / bell.direct   Threads: https://www.threads.net/@bell.direct